Case study - Ceva

CEVA Santé Animale (Animal Health) offers product solutions and services for existing and emerging diseases in the veterinary field, with the aim of improving animal health, productivity of the industrial sector and the prevention of infectious diseases in humans (zoonoses).

The start of 2020 was marked by the renewal of its shareholding structure with new long-term partners investing alongside management and historic minority investors (such as MxEP) with the aim of ensuring the continued independent development of the group.

Ceva is #4 player in the fast-growing segment of biological products within the poultry and swine markets. The company has a strong organic growth complemented by a successful track record in acquiring and integrating distinct assets on a global basis.

Ceva will continue investing in R&D (> 10% of its turnover) and market novel biological products within the poultry and swine market segments to reach its objective of achieving a 50:50 split between vaccine and pharmaceutical sales and double sales by 2025. From a geographical perspective, the company should enhance its position in strategic geographies such as North America and Asia regions. 

Since its initial investment in CEVA in 2014, MxEP has provided support to Ceva on several fronts such as:

• Support to accelerate CEVA’s international expansion in China
• Structure a joint effort on Veterinarian diagnostics (new attractive complementary business for Ceva), leading to evaluation of business segments and of potential acquisitions / licensing opportunities  
• Introduce and/or evaluate new technologies/products on an ongoing basis, which could be of interest to CEVA (animal health applications)
• Give CEVA access to MxEP’s experts network to solve production issues faced in the US